The University of Texas System

Dompé Farmaceutici S.p.a.

Golgi Neurosciences S.r.l.

Dompe S.p.a.

Axxam S.p.a.

Silvia Bovolenta

Chiara Liberati

Philip Jones

Paolo Pevarello

Andrea Aramini

Russell Thomas

Gianluca Bianchini

Alessio Moriconi

Laura Brandolini

William J Ray

Valentina Cusano

Domenica Torino

Francesco Piscitelli

Ali Munaim Yousif

Mary Hamby

Yaima Luzardo Lightfoot

Sandro Colagioia

Andrea Beccari

Simone Lorenzi

Disclosed herein are novel cycloalka[b]heteroaryl compounds having CX3CR1/fractalkine receptor (CX3CR1) agonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment or prophylaxis of diseases associated with CX3CR1 receptor activity in animals, in particular humans.

Bicyclic CX3CR1 receptor agonists

The invention relates to compounds acting as selective antagonists of Transient Receptor Potential cation channel subfamily M member 8 (TRPM8), and having formula:  Said compounds are useful in the treatment of diseases associated with activity of TRPM8 such as pain, inflammation, ischaemia, neurodegeneration, stroke, psychiatric disorders, itch, irritable bowel diseases, cold induced and/or exacerbated respiratory disorders and urological disorders.

TRPM8 antagonists

The invention relates to compounds acting as selective antagonists of Transient Receptor Potential cation channel subfamily M member 8 (TRPM8), and having formula (I). Said compounds are useful in the treatment of diseases associated with activity of TRPM8 such as pain, inflammation, ischaemia, neurodegeneration, stroke, psychiatric disorders, itch, irritable bowel diseases, cold induced and/or exhacerbated respiratory disorders and urological disorders. 

Compounds acting as selective antagonists of Transient Receptor Potential cation channel subfamily M member 8 (hereinafter referred to as TRPM8), having formula: Wherein Said compounds are useful in the prevention and treatment of pathologies depending on TRPM8 activity such as pain, inflammation, ischaemia, neurodegeneration, stroke, psychiatric disorders, inflammatory conditions and urological disorders.

TRPM8 receptor antagonists

Growing community of inventors

Milan, Italy

Silvia Bovolenta